TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18822974

Group type: EXPERIMENTAL
Intervention: Needling method for regulating spleen-stomach (acupuncture at Quchi, Hegu, Xuehai, Zusanli, Yinlingquan, Fenglong, Diji, Sanyinjiao)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine therapy for diabetes mellitus with acupuncture at Weiwanxiashu, Feishu, Pishu, Shenshu, Yanglingquan
Number of subjects: 120
Study: 15846487

Group type: EXPERIMENTAL
Intervention: 3D WB emission acquisitions of 3 min
Number of subjects: 70

Group type: COMPARATOR
Intervention: 2D WB emission acquisitions
Number of subjects: 70
Study: 11790467

Group type: COMPARATOR
Intervention: Ordinary treatment
Number of subjects: 654

Group type: COMPARATOR
Intervention: Light multidisciplinary treatment
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: Extensive multidisciplinary treatment
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: Multidisciplinary treatment
Number of subjects: 654
Study: 10606107

Group type: EXPERIMENTAL
Intervention: Cilostazol plus aspirin (C+A)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Ticlopidine plus aspirin (T+A)
Number of subjects: 300
Study: 8941534

Group type: EXPERIMENTAL
Intervention: 1.5 g HMB/day
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 3.0 g HMB/day
Number of subjects: 69

Group type: COMPARATOR
Intervention: HMB supplementation
Number of subjects: 69
Study: 1668228

Group type: EXPERIMENTAL
Intervention: Stop-smoking program (n = 19)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Wait-list condition (n = 20)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Stop-smoking program
Number of subjects: 39
Study: 6406458

Group type: EXPERIMENTAL
Intervention: bupropion, 50 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: bupropion, 100 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: bupropion, 200 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: bupropion, 100 mg with diazepam, 2.5 and 5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: bupropion, 100 mg with alcohol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: d‐amphetamine, 5 and 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: amitriptyline, 25 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 30666017

Group type: EXPERIMENTAL
Intervention: Cold irrigation at 4°C with 17% EDTA and 10 mL of cold saline solution
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Cold irrigation at 2.5°C with 17% EDTA and 10 mL of cold saline solution
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Room temperature irrigation with 17% EDTA and 10 mL of cold saline solution
Number of subjects: 240
Study: 29364960

Group type: EXPERIMENTAL
Intervention: Empiric TB treatment (n = 82, 49%)
Number of subjects: 4665

Group type: EXPERIMENTAL
Intervention: Chest radiography findings compatible with TB (n = 63/82, 77%)
Number of subjects: 4665

Group type: EXPERIMENTAL
Intervention: Microbiological confirmation of TB
Number of subjects: 4665

Group type: EXPERIMENTAL
Intervention: Median time to empiric treatment start
Number of subjects: 4665
Study: 27477337

Group type: EXPERIMENTAL
Intervention: Naltrexone/Bupropion (NB)
Number of subjects: 2938

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 2938
Study: 24511620

Group type: EXPERIMENTAL
Intervention: Wheat bran sausages
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Rye bran sausages
Number of subjects: 25

Group type: COMPARATOR
Intervention: Wheat flour sausages
Number of subjects: 25

Group type: COMPARATOR
Intervention: Rye bran bread
Number of subjects: 25
Study: 22100188

Group type: EXPERIMENTAL
Intervention: Enriched bread (4% A. nodosum)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control bread (0% A. nodosum)
Number of subjects: 12
Study: 20070752

Group type: EXPERIMENTAL
Intervention: Test group(1) - 4.3 mm platform
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Test group(2) - 4.8 mm platform
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Test group(3) - 5.5 mm platform
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group - 3.8 mm platform
Number of subjects: 31
Study: 17959958

Group type: EXPERIMENTAL
Intervention: 0.015 mg/kg midazolam
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 17599854

Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg in 16 oz of decaffeinated coffee)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Decaffeinated coffee alone (placebo)
Number of subjects: 20
Study: 14722165

Group type: EXPERIMENTAL
Intervention: Words played during surgical stimulation (n=32)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Words played before surgical stimulation (n=32)
Number of subjects: 64
Study: 10866900

Group type: EXPERIMENTAL
Intervention: Dexamethasone before induction of anesthesia (Group 1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dexamethasone at the end of anesthesia (Group 2)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (Group 3)
Number of subjects: 120
Study: 9408719

Group type: EXPERIMENTAL
Intervention: Small meta-analyses (less than 200 outcome events)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Larger meta-analyses (several hundred events)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Well-conducted meta-analyses of large trials using individual patient data
Number of subjects: 0
Study: 1591918

Group type: EXPERIMENTAL
Intervention: Trojan-Enz condom
Number of subjects: 49

Group type: COMPARATOR
Intervention: Tactylon condom
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both condom brands
Number of subjects: 49
Study: 4062332

Group type: EXPERIMENTAL
Intervention: Anthralin minute entire skin treatment (AMEST)
Number of subjects: 43
Study: 31126331

Group type: EXPERIMENTAL
Intervention: CMAB009 plus irinotecan
Number of subjects: 0

Group type: COMPARATOR
Intervention: irinotecan-only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: sequential-CMAB009 therapy
Number of subjects: 0
Study: 28990729

Group type: EXPERIMENTAL
Intervention: Topiroxostat 160 mg daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: Topiroxostat 40 mg daily
Number of subjects: 80
Study: 26507720

Group type: EXPERIMENTAL
Intervention: Riociguat (1 mg and 2 mg doses, three times daily for 6 days)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 24123617

Group type: EXPERIMENTAL
Intervention: Terminalia chebula 10% mouth rinse
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.12% mouth rinse
Number of subjects: 78

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 78
Study: 22646084

Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment (CGA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: CGA in elderly cancer patients (comparison group)
Number of subjects: 50
Study: 21138549

Group type: EXPERIMENTAL
Intervention: Hypnotherapy with positive mood color
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Hypnotherapy with high TAS score
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Hypnotherapy with HAD anxiety
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Combination of positive mood color, HAD anxiety, and high TAS score
Number of subjects: 156
Study: 17909201

Group type: EXPERIMENTAL
Intervention: Telbivudine (group A)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Adefovir (group B)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Adefovir followed by Telbivudine (group C)
Number of subjects: 135
Study: 16304151

Group type: EXPERIMENTAL
Intervention: LOP-TPV
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: LOP-TPV-RTV
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: LOP-RTV
Number of subjects: 24

Group type: COMPARATOR
Intervention: LOP alone
Number of subjects: 24
Study: 11898780

Group type: EXPERIMENTAL
Intervention: Vaccine therapy for melanoma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various vaccine strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cancer immunobiology underlying vaccine therapy
Number of subjects: 0
Study: 9862635

Group type: EXPERIMENTAL
Intervention: Extracellular neurofibrillary tangles (eNFTs) stained with antibodies recognizing the 40 carboxy-terminal of Abeta
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intracellular neurofibrillary tangles (iNFTs) immunoreactive with antibodies to the 42 carboxy-terminal epitope
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tangle associated amyloid deposits (TAADs)
Number of subjects: 0
Study: 7545133

Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg, twice on the test day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2764230

Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg single dose)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 972199

Group type: EXPERIMENTAL
Intervention: 0.50 mg aerosolized terbutaline sulfate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31979057

Group type: EXPERIMENTAL
Intervention: Horticultural therapy (HT)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Comparison group (no specific intervention mentioned)
Number of subjects: 82
Study: 30552510

Group type: EXPERIMENTAL
Intervention: BTX‐A injection
Number of subjects: 26

Group type: COMPARATOR
Intervention: Normal saline injection (Control)
Number of subjects: 26
Study: 28084857

Group type: EXPERIMENTAL
Intervention: 0.1mg/kg Tramadol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.3mg/kg Dexamethasone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 27290958

Group type: EXPERIMENTAL
Intervention: Nicardipine (20 μg/kg intravenous bolus)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Normal saline (comparable volume intravenous bolus)
Number of subjects: 78
Study: 25123526

Group type: EXPERIMENTAL
Intervention: Volume assured non-invasive ventilation (va-NIV)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pressure preset non-invasive ventilation (pp-NIV)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: va-NIV
Number of subjects: 40

Group type: COMPARATOR
Intervention: pp-NIV
Number of subjects: 40
Study: 22538219

Group type: EXPERIMENTAL
Intervention: Topical SAR 1118 0.1%
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Topical SAR 1118 1.0%
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Topical SAR 1118 5.0%
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Topical SAR 1118 (all doses)
Number of subjects: 13
Study: 19159136

Group type: EXPERIMENTAL
Intervention: Manipulated possibility and probability of being stereotyped as unintelligent prior to taking an analytical test
Number of subjects: 0
Study: 17463313

Group type: EXPERIMENTAL
Intervention: NeuroThera Laser System (active treatment)
Number of subjects: 120
Study: 15866309

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine 600 mg daily
Number of subjects: 523

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 523
Study: 14720008

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (Symbicort) 160/4.5 microg, one inhalation twice daily
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (Symbicort)
Number of subjects: 373

Group type: COMPARATOR
Intervention: Fluticasone propionate
Number of subjects: 373
Study: 10554443

Group type: EXPERIMENTAL
Intervention: Pain management flow sheet implementation; protocols derived from AHCPR guidelines; specific details on dosage and duration not available.
Number of subjects: 0
Study: 9772596

Group type: EXPERIMENTAL
Intervention: Fuzheng Huoxue Anticancer prescription (FZHXAC)
Number of subjects: 35
Study: 2010627

Group type: EXPERIMENTAL
Intervention: Cold-adapted influenza B reassortant vaccine
Number of subjects: 75
Study: 7046990

Group type: EXPERIMENTAL
Intervention: Propranolol, 80 mg four times daily
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Verapamil, 80 mg four times daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31891312

Group type: EXPERIMENTAL
Intervention: Loss condition
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Win condition
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 132
Study: 28114980

Group type: EXPERIMENTAL
Intervention: Torasemide
Number of subjects: 120

Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 120
Study: 27111333

Group type: EXPERIMENTAL
Intervention: Cochlear Implant (CI) with standard stimulation pattern (with environmental sound perception)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tinnitus Implant (TI) with looped electrical stimulation (without environmental sound perception)
Number of subjects: 10
Study: 25461783

Group type: EXPERIMENTAL
Intervention: Student Bodies with a guided discussion group (n = 74)
Number of subjects: 151

Group type: COMPARATOR
Intervention: No discussion group (n = 77)
Number of subjects: 151
Study: 21956605

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dabigatran 75 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dabigatran 75 mg twice daily
Number of subjects: 0
Study: 19727062

Group type: EXPERIMENTAL
Intervention: Systematic reviews and meta-analyses
Number of subjects: 0
Study: 17931799

Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemoradiation (RADPLAT)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Gene Set Enrichment analysis
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Previously published signatures for radiosensitivity, hypoxia, proliferation, 'wound,' stem cells, and chromosomal instability
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Recently published signature for HNSCC defining a 'high-risk' group
Number of subjects: 92
Study: 15826233

Group type: EXPERIMENTAL
Intervention: Irrelevant auditory sequence of digits presented in an incongruent order with the visual digits
Number of subjects: 0

Group type: COMPARATOR
Intervention: Irrelevant auditory consonants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Order-incongruence effect
Number of subjects: 0
Study: 12047606

Group type: EXPERIMENTAL
Intervention: Yoku-kan-san-ka-chimpi-hange (YKCH)
Number of subjects: 0
Study: 9389260

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% alone
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% with clonidine 150 micrograms
Number of subjects: 46

Group type: COMPARATOR
Intervention: Bupivacaine with clonidine 150 micrograms i.m. (Control)
Number of subjects: 46
Study: 7957155

Group type: EXPERIMENTAL
Intervention: Rowing
Number of subjects: 25

Group type: COMPARATOR
Intervention: Cycling
Number of subjects: 25

Group type: COMPARATOR
Intervention: Running
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Submaximal rowing
Number of subjects: 25
Study: 3298070

Group type: EXPERIMENTAL
Intervention: Acyclovir (30 mg/kg/day for 10 days)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Vidarabine (15 mg/kg/day for 10 days)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 208

Group type: COMPARATOR
Intervention: Vidarabine
Number of subjects: 208
Study: 30576866

Group type: EXPERIMENTAL
Intervention: Asfotase alfa 0.3 mg/kg/d subcutaneously (SC) for 6 months
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Asfotase alfa 0.5 mg/kg/d SC for 6 months
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Asfotase alfa 0.5 mg/kg/d for 6 months, then 1 mg/kg/d 6 days/week for 4.5 years
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Asfotase alfa (combined group)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 19
Study: 30130784

Group type: EXPERIMENTAL
Intervention: Topical non‐medicated preparations including pH‐lowered preparations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-invasive lipid barrier visualization (Lipbarvis®) technique
Number of subjects: 0
Study: 26630618

Group type: EXPERIMENTAL
Intervention: Increased consumption of evening meals
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80
Study: 24559157

Group type: EXPERIMENTAL
Intervention: MEDI-546 (0.1, 0.3, 1.0, 3.0, 10.0, or 20.0 mg/kg single dose; 0.3, 1.0, or 5.0 mg/kg/week for 4 weeks)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: MEDI-546
Number of subjects: 34
Study: 21766974

Group type: EXPERIMENTAL
Intervention: 200 mg caffeine tablet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-pill control condition
Number of subjects: 0
Study: 19653752

Group type: EXPERIMENTAL
Intervention: Effort manipulation (various conditions differing in environment, type of effort, and intention to act)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Effort manipulation with nonvisual (cognitive) factors considered
Number of subjects: 0
Study: 17567339

Group type: EXPERIMENTAL
Intervention: Fentanyl 0.5 microg.kg(‐1)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Fentanyl 1.0 microg.kg(‐1)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Fentanyl 1.5 microg.kg(‐1)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Fentanyl 2.0 microg.kg(‐1)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 15167310

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE) 0.625 mg/d
Number of subjects: 2673

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE) 0.625 mg/d + medroxyprogesterone acetate (MPA) 2.5 mg/d
Number of subjects: 2673

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE) 0.45 mg/d
Number of subjects: 2673

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE) 0.45 mg/d + medroxyprogesterone acetate (MPA) 2.5 mg/d
Number of subjects: 2673

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE) 0.45 mg/d + medroxyprogesterone acetate (MPA) 1.5 mg/d
Number of subjects: 2673

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE) 0.3 mg/d
Number of subjects: 2673

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE) 0.3 mg/d + medroxyprogesterone acetate (MPA) 1.5 mg/d
Number of subjects: 2673

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2673
Study: 11167328

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced T1-weighted black-blood fast spin-echo MR imaging (BB-FSE)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Contrast-enhanced T1-weighted SE
Number of subjects: 15
Study: 9722068

Group type: EXPERIMENTAL
Intervention: Glutamine (1.0 g amino acid/m2/dose swish and swallow four times a day)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo (glycine)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Glutamine
Number of subjects: 193

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 193
Study: 8116534

Group type: EXPERIMENTAL
Intervention: High A (additional vitamin A in intravenous lipids)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular A (routine vitamin A supplementation)
Number of subjects: 0
Study: 3122696

Group type: EXPERIMENTAL
Intervention: 5% CO2 in patients with panic disorders
Number of subjects: 33

Group type: COMPARATOR
Intervention: 5% CO2 in healthy subjects
Number of subjects: 33

Group type: COMPARATOR
Intervention: 7.5% CO2 in healthy subjects
Number of subjects: 33
Study: 8458450

Group type: EXPERIMENTAL
Intervention: Buserelin acetate 1,200 micrograms/d IN for 6 months (n = 19)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Expectant management (n = 16)
Number of subjects: 35
Study: 282081

Group type: EXPERIMENTAL
Intervention: active therapy
Number of subjects: 1017

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1017

Group type: COMPARATOR
Intervention: no tablets
Number of subjects: 1017

Group type: COMPARATOR
Intervention: non-study control group
Number of subjects: 1017
Study: 30680523

Group type: EXPERIMENTAL
Intervention: Aprepitant (125 mg on day 1 and 80 mg on days 2-3)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Aprepitant delayed 1-day administration (125 mg on day 2 and 80 mg on days 3-4)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Routine triple-antiemetic treatment
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 24
Study: 28357557

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.25 mg/kg diluted to 10 mL with 0.9% saline)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Placebo (10 mL of 0.9% saline)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.25 mg/kg)
Number of subjects: 330
Study: 24902007

Group type: EXPERIMENTAL
Intervention: levomilnacipran extended-release (ER)
Number of subjects: 5

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: levomilnacipran ER
Number of subjects: 5
Study: 23320901

Group type: EXPERIMENTAL
Intervention: S-1 adjuvant therapy (three-week cycle)
Number of subjects: 200

Group type: COMPARATOR
Intervention: S-1 adjuvant therapy (six-week cycle)
Number of subjects: 200
Study: 21187138

Group type: EXPERIMENTAL
Intervention: Individualised herbal prescription
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 19214679

Group type: EXPERIMENTAL
Intervention: Diagnostic ERCP procedures with nonnative papillae (Group A)
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Therapeutic ERCP procedures with nonnative papillae (Group B)
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Diagnostic and therapeutic ERCP procedures with nonnative papillae (Groups A/B)
Number of subjects: 526
Study: 16890769

Group type: EXPERIMENTAL
Intervention: Grass allergen tablet (GRAZAX, ALK‐Abelló, Hørsholm, Denmark) once daily
Number of subjects: 634

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 634
Study: 15345969

Group type: EXPERIMENTAL
Intervention: Early tracheostomy (T group, n = 31)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Prolonged endotracheal intubation (I group, n = 31)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Early tracheostomy (T group) after pneumonia diagnosis
Number of subjects: 62

Group type: COMPARATOR
Intervention: Prolonged endotracheal intubation (I group) after pneumonia diagnosis
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups (T group and I group)
Number of subjects: 62
Study: 11339775

Group type: EXPERIMENTAL
Intervention: Honey
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Glucose-fructose-sucrose-maltose mixture (GFSM)
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Apple juice
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 375

Group type: COMPARATOR
Intervention: Control (overnight fast)
Number of subjects: 375